PET scan could reveal which breast cancer patients will respond to targeted therapy
NCT ID NCT07708922
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study explores whether a Nectin-4 PET scan can predict how well a Nectin-4-targeted therapy works in people with advanced breast cancer. Forty participants will receive both a standard PET scan and a Nectin-4 PET scan before starting treatment, and some will have a repeat scan after one cycle. The goal is to see if the level of Nectin-4 detected by the scan correlates with tumor shrinkage, potentially guiding future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a Nectin-4-targeted agent (therapy) and a Nectin-4 PET imaging agent (68Ga-FZ-NR-1)
- What this could lead to
- If successful, this could help doctors identify which patients are most likely to benefit from Nectin-4-targeted therapy, personalizing treatment and avoiding ineffective drugs.
- What could go wrong
- This is a small, early exploratory study with only 40 participants, so results may not apply broadly. The PET scan's predictive value is unproven, and the therapy itself may still fail in many patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan Cancer Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outsmart resistant breast cancer?
- New drug targets Hard-to-Treat breast cancer in advanced stage
- Could a simple blood test let some breast cancer patients stop treatment?
- New drug cocktail aims to outsmart resistant breast cancer
- Could a targeted drug re-sensitize resistant breast cancer?
- Real-World data may reveal which breast cancer subtype responds best to CDK4/6 inhibitors